dna-istock-518143098-ralwel--2
ralwel / iStockphoto.com
21 November 2023FeaturesBiotechnologyClaire Irvine

The new IP battleground in CRISPR-Cas

While much attention has been focused on the major IP battle affecting foundational patents covering CRISPR-Cas9 systems as gene modifiers, another battle has erupted concerning modified guide ribonucleic acids (RNAs) for use with Cas enzymes. The most visible recent sign of this was the invalidation of all claims of two US Patents of Agilent, US10,900,034 and US10,337,001, by a Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) in inter partes review proceedings instigated by Synthego.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
16 January 2020   In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.
Big Pharma
13 December 2018   France-based biotechnology company genOway has acquired the exclusive global rights to German pharmaceutical company Merck Group’s CRISPR patents, to be used in the production and sale of rodent models.

More on this story

Big Pharma
13 December 2018   France-based biotechnology company genOway has acquired the exclusive global rights to German pharmaceutical company Merck Group’s CRISPR patents, to be used in the production and sale of rodent models.
Europe
16 January 2020   In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

More on this story

Big Pharma
13 December 2018   France-based biotechnology company genOway has acquired the exclusive global rights to German pharmaceutical company Merck Group’s CRISPR patents, to be used in the production and sale of rodent models.
Europe
16 January 2020   In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.